Dergiler / Medicine Science / 2020 / Cilt: 9 - Sayı: 4

Investigation of the effect on prostate cancer purine base analog of the newly developed compound

Sayfa
823–828
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In line with these results, we want to continue our work by applying this heterocyclic compound in different amounts at different time periods.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Prostate cancer is an important cause of death in men.
📊
Temel Bulgular & Veri:This malignant disease is known for excessive proliferation, decreased apoptosis, and uncontrolled proliferation of cells.
💡
Sonuç & Katkı:In line with these results, we want to continue our work by applying this heterocyclic compound in different amounts at different time periods.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Prostate cancer is an important cause of death in men. This malignant disease is known for excessive proliferation, decreased apoptosis, and uncontrolled proliferation of cells. In the light of this knowledge, our aim was to examine potential compounds for their effects on NF-κB and angiogenesis proteins (VGEF, MMP, ES, TSP-1) in a prostate cancer line. In this study, we planned that the purine base analogue with anti-cancer potential has synthesized new compounds, and those with anti-cancer potential has selected by screening with MTT testing. We analysed VEGF, MMP, Endostatin (ES), Thrombospondin-1 (TSP-1) and NF-κB protein levels in a prostate cancer line by the Elisa method. MMA-MEP caused a significant decrease especially for VEGF-A, NF-kB, Endostatin, Thrombospondin -1 and MMP levels compared to other compounds. This suggests that this heterocyclic compound is more effective compared to others. This compound could be more effective for patients with prostate cancer, depending on time and amount. In line with these results, we want to continue our work by applying this heterocyclic compound in different amounts at different time periods.

🔖

Bu Makaleye Atıf Yap

TEMELTAŞ, G., KOSAVA, F., ARPACI, Ö. T., TUĞLU, İ. (2020). Investigation of the effect on prostate cancer purine base analog of the newly developed compound. Medicine Science, Cilt: 9 - Sayı: 4, 823–828. https://ajindex.com/articles/277087

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Arısoy M, Temiz-Arpacı O, Yıldız İ, et al. Synthesis, Antimicrobial activity and QSAR studies of 2,5-disubstituted benzoxazoles, SAR & QSAR Environ. Res. 2008;19;589-612
  2. Arısoy M, Temiz-Arpacı O, Kaynak-Onurdag F, et al. Synthesis and antimicrobial evaluation of 2-(p-SubstitutedPhenyl)-5-[(4-substituted piperazin-1-yl)acetamido]-benzoxazoles. Z Naturforsch. 2014;69;368-74
  3. Temiz-Arpaci O, Doğanç F, Saç D, et al. Synthesis and antimicrobial evaluation of some sulfonylamido-benzoxazoles. Acta Biol. Hung. 2016;67:75-84
  4. Brown RN, Cameron R, Chalmers DK, et al. 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. Bioorg Med Chem Letters. 2005;15:2051-5
  5. Rida SM, Ashour FA, El-Hawash SAM, et al. Synthesis of some novel benzoxazole derivatives as anticancer, anti-HIV-1 and antimicrobial agents. Eur J Med Chem. 2005;40:949-59
  6. Oksuzoglu E, Tekiner-Gulbas B, Alper S, et al. Some benzoxazoles and benzimidazoles as DNA topoisomerase I and II inhibitors. J Enzyme Inhib Med Chem 2008;23:37–42
  7. Pınar A, Yurdakul P, Yıldız I, et al. Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors. Biochem Biophys Res Commun. 2004;317:670
  8. Oksuzoglu E, Temiz-Arpaci O, Tekiner-Gulbas B, et al. A study on the genotoxic activities of some new benzoxazoles. Med Chem Res. 2007;16:1-14
  9. Varga A, Akı-Sener E, et al. Induction of apoptosis and necrosis by resistance benzazoles and benzoxazines on tumour cell line mouselymphoma L5718 Mdr+cells. In Vivo. 2005;19:1087-92
  10. Temiz-Arpaci O, Coban T, Tekiner-Gulbas B, et al. A study on the antioxidant activities of some new benzazole derivatives. Acta Biol Hungarica. 2006;57:201-9
  11. Gungorduk K, Ertas IE, Sahbaz A, et al. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic signifi cance in malignant group. Eur J Obstet Gynecol Reprod Biol. 2014;179:147–52
  12. Muvaffak A, Gurhan I, Gunduz U, et al. Preparation and characterization of a biodegradable drug targeting system for anticancer drug delivery: microsphereantibody conjugate. J Drug Targ. 2005;13:151–9
  13. Wiśniewski T, Żyromska A, Makarewicz R, et al. Osteopontin and angiogenic factors as new biomarkers of prostate cancer. Urological Oncology. 2019;16:134-40
  14. Heidtmann HH, Nettelbeck DM, Mingels A, et al. Generation of angiostatinlike fragm